{"meta":{"query_hash":"89fb22847ca8","filters":{"venue":"ESMO Gastrointestinal Oncology"},"cohort_total":13,"direct_labels_cover":0,"predictions_cover":13,"exported":13,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/89fb22847ca8","api":"https://metacan.xera.ac/api/v1/cohort?venue=ESMO+Gastrointestinal+Oncology"},"results":[{"id":"W4395063719","doi":"10.1016/j.esmogo.2024.100055","title":"Second-line FOLFOX chemotherapy for patients with advanced biliary tract cancers pretreated with cisplatin/gemcitabine: a systematic review and meta-analysis","year":2024,"lang":"en","type":"review","venue":"ESMO Gastrointestinal Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University","funders":"","keywords":"Gemcitabine; FOLFOX; Cisplatin; Medicine; Oncology; Chemotherapy; Internal medicine; Meta-analysis; Biliary tract cancer; Biliary tract; Oxaliplatin; Cancer; Colorectal cancer","score_opus":0.0422038696584239,"score_gpt":0.34847401023102614,"score_spread":0.30627014057260227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395063719","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005823698,0.9926167,0.0003250452,0.0001364201,0.000087579385,0.000211032,0.0005460235,0.000018258188,0.00023527867],"genre_scores_gemma":[0.1774513,0.8176709,0.0015162216,0.00089928263,0.00018476891,0.00076963665,0.0011016438,0.000026991474,0.0003792416],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99638927,0.0014007981,0.0011736588,0.00046256857,0.00041855517,0.00015511848],"domain_scores_gemma":[0.99243367,0.004928797,0.0015605853,0.00023266395,0.0007012231,0.00014313888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062481803,0.0018811373,0.013773887,0.0053516435,0.00045878408,0.0020216221,0.0016604846,0.0016084587,0.003568625],"category_scores_gemma":[0.012431252,0.0010217938,0.029005164,0.0064599724,0.00043273647,0.0012998855,0.0010133572,0.0012506691,0.00029310584],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018701878,0.000035309127,0.004411794,0.4587757,0.52079314,0.00014443301,0.00008179188,0.00049344596,0.000298656,0.00010446884,0.0007667042,0.012224324],"study_design_scores_gemma":[0.00043965215,0.00019675835,0.0045956816,0.02489205,0.9674508,0.000110902045,0.00004266189,0.00016048996,0.0001160954,0.00011176323,0.0018593244,0.0000238311],"about_ca_topic_score_codex":0.005726154,"about_ca_topic_score_gemma":0.01545422,"teacher_disagreement_score":0.013773887,"about_ca_system_score_codex":0.0019426091,"about_ca_system_score_gemma":0.0024304355,"threshold_uncertainty_score":0.03304392},"labels":[],"label_agreement":null},{"id":"W4404756549","doi":"10.1016/j.esmogo.2024.100107","title":"PD-L1 as a response biomarker to chemotherapy plus immune checkpoint inhibitors in operable gastroesophageal adenocarcinoma: a meta-analysis of neoadjuvant clinical trials","year":2024,"lang":"en","type":"article","venue":"ESMO Gastrointestinal Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Global Health Research","funders":"NIHR Oxford Biomedical Research Centre; AstraZeneca","keywords":"Meta-analysis; Medicine; Oncology; Biomarker; Chemotherapy; Internal medicine; Neoadjuvant therapy; Complete response; Immune checkpoint; Clinical trial; Immunotherapy; Cancer; Biology; Breast cancer","score_opus":0.17252356598905416,"score_gpt":0.4599136091919914,"score_spread":0.28739004320293726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404756549","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017751243,0.9796308,0.00084271154,0.00030453262,0.000217946,0.000246355,0.000583404,0.0000330922,0.00038985396],"genre_scores_gemma":[0.6521025,0.3394542,0.0031883616,0.0016292316,0.00047475062,0.0011433805,0.0014020606,0.00007418944,0.0005314146],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9832424,0.009946958,0.0038574906,0.0016133385,0.0010148673,0.0003250632],"domain_scores_gemma":[0.969081,0.023478007,0.0048403307,0.0010887966,0.0011378272,0.00037412898],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.02047716,0.00254985,0.015932089,0.0040487386,0.0005161695,0.0035267181,0.0017919017,0.0020623687,0.0023687345],"category_scores_gemma":[0.037201844,0.0014158107,0.04567451,0.005047813,0.00092371774,0.0016260032,0.0013668265,0.0023449543,0.00030495648],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058488217,0.000029034147,0.0061685033,0.09079984,0.89059037,0.00007175432,0.000039936764,0.0006749434,0.00024053274,0.000080952006,0.0002308073,0.0052244226],"study_design_scores_gemma":[0.0008402755,0.00028636766,0.0033561438,0.0038596904,0.9905906,0.000045715035,0.00001867051,0.00021706423,0.00008615621,0.00013516517,0.00055134087,0.000012831355],"about_ca_topic_score_codex":0.003548243,"about_ca_topic_score_gemma":0.005988179,"teacher_disagreement_score":0.9840679,"about_ca_system_score_codex":0.001903128,"about_ca_system_score_gemma":0.0016876897,"threshold_uncertainty_score":0.108294845},"labels":[],"label_agreement":null},{"id":"W4404948696","doi":"10.1016/j.esmogo.2024.100111","title":"This is not Lynch syndrome: lessons from misattributed diagnoses in constitutional mismatch repair deficiency","year":2024,"lang":"en","type":"article","venue":"ESMO Gastrointestinal Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; McGill University; McGill University Health Centre","funders":"","keywords":"Lynch syndrome; Medicine; DNA mismatch repair; Internal medicine; Cancer","score_opus":0.04332672606377994,"score_gpt":0.3450683556783465,"score_spread":0.3017416296145665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404948696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47519162,0.0972683,0.036885224,0.35572946,0.008579304,0.00017518352,0.00072551577,0.0004320201,0.025013436],"genre_scores_gemma":[0.9491816,0.023767445,0.009584935,0.012662737,0.0036165353,0.00002438897,0.0001298755,0.000084305044,0.0009480854],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9949486,0.002501535,0.0006106498,0.00057759025,0.0010235114,0.0003380641],"domain_scores_gemma":[0.9674237,0.020447902,0.0051108343,0.002085829,0.0034679957,0.001463885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009331852,0.00039592,0.0005146021,0.0019609213,0.0013221408,0.0022923728,0.0011319191,0.0019993817,0.0011655033],"category_scores_gemma":[0.0635196,0.00034820617,0.00030486606,0.0012053037,0.0029788297,0.0048965802,0.0021458461,0.0033681984,0.00046123727],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031310113,0.00009638345,0.53524673,0.00083081744,0.00015638849,0.086333744,0.016846174,0.0011301133,0.001071665,0.017452607,0.04970063,0.29082164],"study_design_scores_gemma":[0.00008626143,0.00051558495,0.22495392,0.006787784,0.00021596251,0.45843226,0.061386075,0.0059807934,0.002117059,0.09728463,0.14189059,0.00034900167],"about_ca_topic_score_codex":0.0061888853,"about_ca_topic_score_gemma":0.0075991424,"teacher_disagreement_score":0.009331852,"about_ca_system_score_codex":0.0014771298,"about_ca_system_score_gemma":0.0015891916,"threshold_uncertainty_score":0.04935217},"labels":[],"label_agreement":null},{"id":"W4406071945","doi":"10.1016/j.esmogo.2024.100115","title":"Eligibility and workload implications of adjuvant immunotherapy in patients with resected esophageal and gastroesophageal junction (ESO/GEJ) cancer","year":2025,"lang":"en","type":"article","venue":"ESMO Gastrointestinal Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Gastroesophageal Junction; Adjuvant; Medicine; Esophageal cancer; Esophagogastric junction; Workload; Immunotherapy; Internal medicine; Oncology; Cancer; Gastroenterology; Adenocarcinoma; Computer science","score_opus":0.01117862969184222,"score_gpt":0.3389754747281391,"score_spread":0.32779684503629686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406071945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929733,0.0008788504,0.00029812686,0.0017509534,0.0000263784,0.000119741155,0.0015456775,0.0000036645158,0.002403284],"genre_scores_gemma":[0.998487,0.00016268952,0.00020397881,0.00023595727,0.00003777005,0.000076262026,0.00069383456,0.000003201511,0.00009929469],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99257785,0.004373214,0.00082368095,0.0005996248,0.00092786894,0.00069774245],"domain_scores_gemma":[0.98524046,0.004732142,0.0073527596,0.00044209676,0.0009186046,0.001314057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004873313,0.00011780456,0.00027289512,0.0008998364,0.00063144864,0.0011724221,0.0006551941,0.00031843764,0.002051503],"category_scores_gemma":[0.025446719,0.00013483313,0.00043578487,0.0014030795,0.0005156718,0.0006270321,0.0011000586,0.00048127363,0.00021154582],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053605164,0.000067036366,0.9878842,0.000048694572,0.000035844805,0.00009798981,0.00014963193,0.0003075177,0.00010283298,0.0002708934,0.0013836726,0.009115668],"study_design_scores_gemma":[0.000059355185,0.00025735426,0.9925518,0.000106801024,0.000054139873,0.00033367923,0.0010356541,0.0019255929,0.00019929135,0.00053918746,0.002922926,0.000014217231],"about_ca_topic_score_codex":0.007150321,"about_ca_topic_score_gemma":0.013996235,"teacher_disagreement_score":0.007150321,"about_ca_system_score_codex":0.0015320487,"about_ca_system_score_gemma":0.0017758969,"threshold_uncertainty_score":0.02577287},"labels":[],"label_agreement":null},{"id":"W4408107594","doi":"10.1016/j.esmogo.2025.100138","title":"GATA6 immunohistochemistry and prognosis after surgical resection of pancreatic adenocarcinoma: results from the ESPAC-4 trial","year":2025,"lang":"en","type":"article","venue":"ESMO Gastrointestinal Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Ontario Institute for Cancer Research","funders":"Canadian Friends of Hebrew University; Terry Fox Research Institute; Pancreatic Cancer Canada Foundation; Canadian Cancer Society; Ontario Institute for Cancer Research; Princess Margaret Cancer Foundation; Canadian Cancer Society Research Institute; Cancer Research Society","keywords":"Surgical resection; Immunohistochemistry; Adenocarcinoma; Medicine; Resection; Surgical pathology; Pancreatic ductal adenocarcinoma; Internal medicine; Pathology; Oncology; Pancreatic cancer; Surgery; Cancer","score_opus":0.024722022828255242,"score_gpt":0.3524713574561309,"score_spread":0.32774933462787564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408107594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99677557,0.0022820474,0.00008892032,0.00008504968,0.000019265004,0.0000245159,0.00029212737,0.000005092494,0.0004273951],"genre_scores_gemma":[0.9984779,0.00033499926,0.00011889509,0.00007805976,0.000029387456,0.00002556616,0.0007490379,0.0000018120364,0.00018436482],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994448,0.00029561832,0.000051569063,0.000075431315,0.00008799139,0.000044571247],"domain_scores_gemma":[0.9989483,0.00036279322,0.00035075523,0.00011224589,0.00008496141,0.00014107068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018455714,0.0003116576,0.00044986446,0.00016865051,0.00011858504,0.00040830966,0.00024277504,0.00036379238,0.0011514742],"category_scores_gemma":[0.0015772787,0.000108777145,0.00088053034,0.00024428358,0.00024269751,0.00030535183,0.00026010533,0.00047234105,0.00011258901],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33121872,0.0006961999,0.5959206,0.0007903286,0.00596511,0.00015998537,0.0000938444,0.0019652676,0.0070171747,0.00014214136,0.0017828359,0.054247893],"study_design_scores_gemma":[0.03082414,0.022843774,0.9288012,0.00015989183,0.006827017,0.00056962896,0.00013452022,0.0024481255,0.0035041254,0.00044982834,0.0034000303,0.000037696544],"about_ca_topic_score_codex":0.00030144607,"about_ca_topic_score_gemma":0.00075937057,"teacher_disagreement_score":0.0018455714,"about_ca_system_score_codex":0.00023952057,"about_ca_system_score_gemma":0.0001797606,"threshold_uncertainty_score":0.009760439},"labels":[],"label_agreement":null},{"id":"W4409196276","doi":"10.1016/j.esmogo.2025.100159","title":"Quantitative benefit–risk assessment of data from the phase III ClarIDHy study of ivosidenib versus placebo in patients with mIDH1 cholangiocarcinoma","year":2025,"lang":"en","type":"article","venue":"ESMO Gastrointestinal Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital","funders":"Servier","keywords":"Placebo; Medicine; Oncology; Pathology; Alternative medicine","score_opus":0.05982271673490667,"score_gpt":0.3929638768447898,"score_spread":0.3331411601098831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409196276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8816018,0.026349543,0.06845866,0.0027322313,0.00026452224,0.0056454125,0.007257451,0.00023192578,0.007458372],"genre_scores_gemma":[0.9868687,0.0011437916,0.008643551,0.00033863535,0.00005343319,0.0009797855,0.0016095128,0.000028767918,0.00033391346],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9390375,0.05443203,0.0019437616,0.0012579178,0.0029973504,0.0003314667],"domain_scores_gemma":[0.87404335,0.10414077,0.014514427,0.0034356778,0.0031268361,0.0007389746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.07096426,0.0012761524,0.0021976524,0.0010773527,0.00026319842,0.0016397107,0.00089243444,0.0009262551,0.0030627325],"category_scores_gemma":[0.08023323,0.0004115759,0.0060674404,0.0007760141,0.0007120231,0.0010929175,0.0009925762,0.002621618,0.0002792056],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39862943,0.0033973784,0.09041266,0.0148776425,0.060762215,0.0003643272,0.0011365996,0.17375654,0.009922259,0.005971525,0.0066428944,0.23412661],"study_design_scores_gemma":[0.08914568,0.1951945,0.2069937,0.006686542,0.052483104,0.0016115645,0.0009875363,0.34297916,0.024094082,0.045093793,0.033972215,0.0007581075],"about_ca_topic_score_codex":0.00039572964,"about_ca_topic_score_gemma":0.00056632754,"teacher_disagreement_score":0.07096426,"about_ca_system_score_codex":0.0012676042,"about_ca_system_score_gemma":0.001109919,"threshold_uncertainty_score":0.3752994},"labels":[],"label_agreement":null},{"id":"W4410517924","doi":"10.1016/j.esmogo.2025.100172","title":"Esophageal microbiome correlates with post-esophagectomy anastomotic leak in cancer patients","year":2025,"lang":"en","type":"article","venue":"ESMO Gastrointestinal Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Institute for Advanced Research","funders":"Technion-Israel Institute of Technology; European Commission; European Research Council; Human Frontier Science Program; Seerave Foundation; Canadian Institute for Advanced Research; Israel Science Foundation; Israel Cancer Research Fund","keywords":"Esophagectomy; Microbiome; Leak; Esophageal cancer; Medicine; Anastomosis; Cancer; General surgery; Surgery; Internal medicine; Biology; Bioinformatics; Engineering","score_opus":0.011218847868939534,"score_gpt":0.31862713575069773,"score_spread":0.3074082878817582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410517924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998185,0.0009487182,0.00011388718,0.0000786739,0.000011404396,0.0000071671698,0.00024213376,0.000003374063,0.0004096259],"genre_scores_gemma":[0.9992205,0.00024483362,0.00015449536,0.00003182478,0.000008591351,0.0000070607325,0.00023460627,0.0000014608576,0.00009654767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997689,0.00005810404,0.000031745065,0.00004401754,0.000039003557,0.000058268626],"domain_scores_gemma":[0.9994814,0.00008389357,0.00024077493,0.000022002305,0.00007281046,0.00009915244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025148154,0.00014586994,0.0002397593,0.00041920927,0.00029724996,0.0005167799,0.000115135976,0.00034885944,0.0016301406],"category_scores_gemma":[0.0015344847,0.00009827262,0.00022034254,0.00062877743,0.00016210004,0.00028306042,0.0004544281,0.0003716011,0.00018342184],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017277591,0.000032592463,0.9953578,0.000030242869,0.000030362975,0.00012628156,0.00006766156,0.00003168673,0.0011673351,0.000014415914,0.00014501702,0.0028238478],"study_design_scores_gemma":[0.00000297456,0.00009868555,0.9982476,0.000017821863,0.000029850078,0.00048643965,0.00031545362,0.00019498303,0.00022847104,0.000039087492,0.00033461742,0.0000039532615],"about_ca_topic_score_codex":0.0009313307,"about_ca_topic_score_gemma":0.0014407783,"teacher_disagreement_score":0.0016301406,"about_ca_system_score_codex":0.00017613043,"about_ca_system_score_gemma":0.00018922368,"threshold_uncertainty_score":0.005453348},"labels":[],"label_agreement":null},{"id":"W4411887265","doi":"10.1016/j.esmogo.2025.100190","title":"Systemic adjuvant and perioperative chemotherapy following curative-intent liver metastasectomy in colorectal cancer—is it justified?","year":2025,"lang":"en","type":"article","venue":"ESMO Gastrointestinal Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Metastasectomy; Medicine; Colorectal cancer; Perioperative; Adjuvant chemotherapy; Chemotherapy; General surgery; Adjuvant; Oncology; Cancer; Internal medicine; Surgery","score_opus":0.05475863086939123,"score_gpt":0.33135006230164155,"score_spread":0.2765914314322503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411887265","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4050743,0.5250648,0.0031126773,0.049192924,0.0022980936,0.00010333434,0.0005126652,0.00006805738,0.014573029],"genre_scores_gemma":[0.92270964,0.06877654,0.0011469969,0.004483207,0.0017154213,0.000055758614,0.00025739553,0.000020875827,0.00083419535],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99884254,0.0006487308,0.00015286668,0.00008779583,0.00017157767,0.00009653186],"domain_scores_gemma":[0.99590296,0.0017035052,0.0014089012,0.00019618205,0.0004143655,0.0003741774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022283676,0.00012379268,0.00058043987,0.00025009183,0.00019378716,0.0010419129,0.00025359602,0.0005137542,0.0017845103],"category_scores_gemma":[0.010646522,0.000077114186,0.0004060448,0.00038220698,0.0005473264,0.0010943272,0.00030926513,0.0008097293,0.000339748],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070575876,0.00024447715,0.10642891,0.0025430077,0.0006220499,0.00046659927,0.00030173903,0.0009197954,0.0015162925,0.0031357796,0.010074201,0.8666895],"study_design_scores_gemma":[0.0019336654,0.018431466,0.6006251,0.017985826,0.00631195,0.010521497,0.0040225037,0.006379736,0.008276335,0.03277477,0.29243067,0.0003064787],"about_ca_topic_score_codex":0.00063207967,"about_ca_topic_score_gemma":0.0023913067,"teacher_disagreement_score":0.0022283676,"about_ca_system_score_codex":0.0005265197,"about_ca_system_score_gemma":0.0012537416,"threshold_uncertainty_score":0.011784852},"labels":[],"label_agreement":null},{"id":"W4413126866","doi":"10.1016/j.esmogo.2025.100220","title":"ESMO Podcast on upper gastrointestinal cancers—highlights in biliary and pancreatic cancers from ASCO 2025","year":2025,"lang":"en","type":"article","venue":"ESMO Gastrointestinal Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University Health Network","funders":"Astellas Pharma; AstraZeneca; Amgen","keywords":"Medicine; Internal medicine; Gastroenterology; General surgery; Oncology","score_opus":0.018025544828466963,"score_gpt":0.2977784100308122,"score_spread":0.2797528652023452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413126866","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0080876695,0.2853776,0.0005623518,0.2885389,0.23952842,0.00033685114,0.09878791,0.000463871,0.07831638],"genre_scores_gemma":[0.04918639,0.33666262,0.0021539705,0.12576173,0.30534288,0.0005868708,0.09469061,0.0005492135,0.085065655],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998818,0.0002609313,0.00015759982,0.00010830811,0.0003569988,0.0002981123],"domain_scores_gemma":[0.99096453,0.0021129646,0.0013021603,0.00027143816,0.002194789,0.003154161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003893267,0.000628044,0.0008908028,0.0032611256,0.0007141954,0.0033690035,0.00077308394,0.002259216,0.046375167],"category_scores_gemma":[0.0104362285,0.00043707312,0.0015511173,0.0036487125,0.0003100924,0.0017560049,0.0030337768,0.002397447,0.009925274],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002404136,0.000025111112,0.0026411423,0.001066569,0.000054403445,0.000038113252,0.000019877942,0.000030107884,0.000050202136,0.0004016918,0.95301646,0.042415842],"study_design_scores_gemma":[0.00013809683,0.00008844951,0.028793378,0.0039956328,0.00016934071,0.000118598866,0.00015259099,0.000053468728,0.00006479163,0.00044417288,0.96596277,0.000018705761],"about_ca_topic_score_codex":0.009172392,"about_ca_topic_score_gemma":0.02362579,"teacher_disagreement_score":0.046375167,"about_ca_system_score_codex":0.0015764282,"about_ca_system_score_gemma":0.0043518445,"threshold_uncertainty_score":0.15514034},"labels":[],"label_agreement":null},{"id":"W4414438515","doi":"10.1016/j.esmogo.2025.100239","title":"Drug dose optimization and substitutions to improve access for patients with gastrointestinal and neuroendocrine cancers","year":2025,"lang":"en","type":"article","venue":"ESMO Gastrointestinal Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Limiting; Drug; Paclitaxel; Neuroendocrine tumors; Cancer; Chemotherapy; Immunotherapy","score_opus":0.01378563512465928,"score_gpt":0.3365995881075995,"score_spread":0.3228139529829402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414438515","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2348037,0.29348332,0.08160307,0.19110605,0.005328518,0.0024999043,0.00250558,0.001968972,0.18670085],"genre_scores_gemma":[0.74113715,0.11394427,0.07994397,0.034831315,0.0040665097,0.0012805143,0.0021738587,0.00037472253,0.022247707],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992125,0.00037182943,0.00012119537,0.00007317243,0.00014152484,0.0000798084],"domain_scores_gemma":[0.998494,0.00050727674,0.00040813498,0.00010247179,0.00023028773,0.00025769635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001174198,0.00027751824,0.0004823959,0.0006477908,0.0002902541,0.0010120171,0.0005822548,0.0007017476,0.01275161],"category_scores_gemma":[0.0060147177,0.00009693055,0.00086975476,0.00052474986,0.00025679334,0.0011963095,0.0007659909,0.0015184719,0.0019386534],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013421727,0.0010938402,0.010600494,0.0014354249,0.00022971418,0.0005639335,0.00019630908,0.0034254761,0.0030869239,0.007547224,0.042779207,0.9276993],"study_design_scores_gemma":[0.0019286514,0.0050555295,0.05896036,0.004037568,0.0011027596,0.005681397,0.00085190113,0.0072316774,0.009980909,0.032789122,0.8722146,0.00016558004],"about_ca_topic_score_codex":0.00088543363,"about_ca_topic_score_gemma":0.0020379596,"teacher_disagreement_score":0.01275161,"about_ca_system_score_codex":0.0006468651,"about_ca_system_score_gemma":0.0013042749,"threshold_uncertainty_score":0.04265839},"labels":[],"label_agreement":null},{"id":"W4415479210","doi":"10.1016/j.esmogo.2025.100259","title":"The impact of socioeconomic status with overall survival in hepatocellular carcinoma: a systematic review and meta-analysis","year":2025,"lang":"en","type":"article","venue":"ESMO Gastrointestinal Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Medical Research Council; Ministry of Health -Singapore; SingHealth","keywords":"Socioeconomic status; Hazard ratio; Overall survival; Cohort study; Cohort; Cancer survival; Confidence interval; Proportional hazards model; Meta-analysis","score_opus":0.03370398363045073,"score_gpt":0.28605503170481245,"score_spread":0.2523510480743617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415479210","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005784572,0.99257654,0.00041887016,0.0001980362,0.00010396329,0.00013986521,0.0005720105,0.00001773103,0.00018834244],"genre_scores_gemma":[0.22753684,0.76760453,0.001670776,0.0007083875,0.00029089706,0.000761581,0.0010820276,0.00003081854,0.0003141567],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9931833,0.0035553928,0.001672732,0.00069551886,0.00062610995,0.0002670299],"domain_scores_gemma":[0.9828662,0.013237871,0.0022682408,0.00044315253,0.0009673038,0.00021719186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010578091,0.0026365723,0.014218234,0.005687611,0.00058994605,0.0028280213,0.0018856479,0.0019538584,0.0031667722],"category_scores_gemma":[0.026626633,0.0012101152,0.040430136,0.0062068077,0.0006911423,0.0014299456,0.0014461303,0.0016129707,0.00022865074],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00163202,0.000026688722,0.006572809,0.25836498,0.7220733,0.0001269627,0.000061396146,0.0008931264,0.00014314677,0.00011760005,0.0005326857,0.009455226],"study_design_scores_gemma":[0.00028296717,0.0001447223,0.004891739,0.015096305,0.9779814,0.0000816453,0.000029939541,0.00023302942,0.00006898711,0.00016782303,0.0010021325,0.000019368432],"about_ca_topic_score_codex":0.008936384,"about_ca_topic_score_gemma":0.0152142625,"teacher_disagreement_score":0.014218234,"about_ca_system_score_codex":0.0022224223,"about_ca_system_score_gemma":0.0028378507,"threshold_uncertainty_score":0.055943012},"labels":[],"label_agreement":null},{"id":"W7084142318","doi":"10.1016/j.esmogo.2025.100243","title":"The impact of socioeconomic status on overall survival in patients with colorectal cancer: a systematic review and meta-analysis","year":2025,"lang":"en","type":"article","venue":"ESMO Gastrointestinal Oncology","topic":"Bacteriophages and microbial interactions","field":"Environmental Science","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Medical Research Council; Medical Research Council; Ministry of Health -Singapore; SingHealth","keywords":"Socioeconomic status; Hazard ratio; Cohort study; Psychological intervention; Cohort; Overall survival; Proportional hazards model; Colorectal cancer; Neighbourhood (mathematics); Confidence interval","score_opus":0.010927069194791745,"score_gpt":0.2963622984286986,"score_spread":0.28543522923390685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7084142318","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0062416447,0.9919425,0.00046538425,0.00020546016,0.00011001896,0.00016347456,0.0006577256,0.00002024314,0.00019359542],"genre_scores_gemma":[0.2285443,0.7660757,0.0020482573,0.0007213142,0.00028198058,0.00086683186,0.0011254606,0.000029236273,0.00030690574],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9926173,0.003713622,0.0018221824,0.00082371326,0.0007560433,0.00026724042],"domain_scores_gemma":[0.98391855,0.012260931,0.0022862032,0.00042711108,0.0008812283,0.0002259371],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010771933,0.0028031,0.015396704,0.0067530638,0.0005889556,0.003058785,0.0020094258,0.0021215596,0.003050789],"category_scores_gemma":[0.02720987,0.001287682,0.044667255,0.006982815,0.00074267486,0.0016299046,0.0015105249,0.0016926313,0.00021294339],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013640727,0.000027685914,0.006595957,0.26377216,0.7172051,0.00011994051,0.000060815593,0.0009040371,0.00012224582,0.0001195007,0.00050511747,0.009203445],"study_design_scores_gemma":[0.0003008518,0.00015563305,0.00521212,0.017113019,0.9754588,0.00008607037,0.000035452093,0.0002644001,0.0000627643,0.0001698683,0.0011196677,0.000021410639],"about_ca_topic_score_codex":0.009022747,"about_ca_topic_score_gemma":0.016569152,"teacher_disagreement_score":0.015396704,"about_ca_system_score_codex":0.002337729,"about_ca_system_score_gemma":0.003053138,"threshold_uncertainty_score":0.056968093},"labels":[],"label_agreement":null},{"id":"W7114985703","doi":"10.1016/j.esmogo.2025.100277","title":"ESMO podcast on upper GI cancers: highlights in hepatocellular carcinoma and pancreatic cancer from ESMO 2025","year":2025,"lang":"en","type":"article","venue":"ESMO Gastrointestinal Oncology","topic":"Social Media in Health Education","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital","funders":"National Cancer Institute; Stand Up To Cancer; National Institutes of Health; American Society of Clinical Oncology; American Association for Cancer Research","keywords":"Hepatocellular carcinoma; Pancreatic cancer; Pancreatic carcinoma; Cancer; Carcinoma; Clinical Oncology","score_opus":0.05597901667857572,"score_gpt":0.37902605169185616,"score_spread":0.3230470350132804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7114985703","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013412156,0.10526729,0.00025212424,0.4642344,0.39988375,0.00010556874,0.002272694,0.00017959371,0.026463367],"genre_scores_gemma":[0.010362377,0.10045905,0.00059627095,0.20869164,0.6012538,0.0002180295,0.0030434232,0.00020101856,0.07517442],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998626,0.000308325,0.00015039879,0.00014544088,0.00048358386,0.00028632523],"domain_scores_gemma":[0.9909861,0.002545026,0.00083409395,0.00017973398,0.0018475577,0.0036074966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039220206,0.001034217,0.0010630616,0.0026551802,0.0023702967,0.0059111,0.0010565489,0.007950663,0.03386297],"category_scores_gemma":[0.0114924945,0.00055282,0.001492148,0.0021432075,0.0010328365,0.004143972,0.0049618613,0.010175261,0.0097815525],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003477727,0.000015262565,0.00014612467,0.00019478433,0.0000051962793,0.0000562644,0.00003378391,0.000015443124,0.000032324013,0.00031605552,0.98505116,0.014098811],"study_design_scores_gemma":[0.00002290142,0.000038215563,0.0018265449,0.0008931355,0.000013146263,0.00013315931,0.0001760429,0.000029694012,0.000035201898,0.00041216638,0.9964085,0.00001135163],"about_ca_topic_score_codex":0.0050993734,"about_ca_topic_score_gemma":0.013272245,"teacher_disagreement_score":0.03386297,"about_ca_system_score_codex":0.0033722923,"about_ca_system_score_gemma":0.003432684,"threshold_uncertainty_score":0.11328292},"labels":[],"label_agreement":null}]}